Literature DB >> 21760537

Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.

Toru Yasuda1, Hideki Hayakawa, Tomoko Nihira, Yong-Ri Ren, Yasuto Nakata, Makiko Nagai, Nobutaka Hattori, Koichi Miyake, Masahiko Takada, Takashi Shimada, Yoshikuni Mizuno, Hideki Mochizuki.   

Abstract

Loss-of-function mutations in the ubiquitin ligase parkin are the major cause of recessively inherited early-onset Parkinson disease (PD). Impairment of parkin activity caused by nitrosative or dopamine-related modifications may also be responsible for the loss of dopaminergic (DA) neurons in sporadic PD. Previous studies have shown that viral vector-mediated delivery of parkin prevented DA neurodegeneration in several animal models, but little is known about the neuroprotective actions of parkin in vivo. Here, we investigated mechanisms of neuroprotection of overexpressed parkin in a modified long-term mouse model of PD using osmotic minipump administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Recombinant adeno-associated viral vector-mediated intranigral delivery of parkin prevented motor deficits and DA cell loss in the mice. Ser129-phosphorylated α-synuclein-immunoreactive cells were increased in the substantia nigra of parkin-treated mice. Moreover, delivery of parkin alleviated the MPTP-induced decrease of the active phosphorylated form of Akt. On the other hand, upregulation of p53 and mitochondrial alterations induced by chronic MPTP administration were barely suppressed by parkin. These results suggest that the neuroprotective actions of parkin may be impaired in severe PD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21760537     DOI: 10.1097/NEN.0b013e3182269ecd

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  31 in total

Review 1.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

Review 2.  Gene therapy targeting mitochondrial pathway in Parkinson's disease.

Authors:  Chi-Jing Choong; Hideki Mochizuki
Journal:  J Neural Transm (Vienna)       Date:  2016-09-16       Impact factor: 3.575

Review 3.  Role of the ubiquitin-proteasome system in nervous system function and disease: using C. elegans as a dissecting tool.

Authors:  Márcio S Baptista; Carlos B Duarte; Patrícia Maciel
Journal:  Cell Mol Life Sci       Date:  2012-03-03       Impact factor: 9.261

4.  Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.

Authors:  Xiaotian Sun; Pascaline Aimé; David Dai; Nagendran Ramalingam; John F Crary; Robert E Burke; Lloyd A Greene; Oren A Levy
Journal:  Exp Neurol       Date:  2018-02-09       Impact factor: 5.330

5.  The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.

Authors:  Matthew J Benskey; Fredric P Manfredsson; Keith J Lookingland; John L Goudreau
Journal:  Neurotoxicology       Date:  2014-11-20       Impact factor: 4.294

6.  Effect of isoflurane + N2O inhalation and propofol + fentanyl anesthesia on myocardial function as assessed by cardiac troponin, caspase-3, cyclooxygenase-2 and inducible nitric oxide synthase expression.

Authors:  Zhuanghui Zhu; Shuanglian Yi; Zhonggui Shan; Hongwei Guo; Shaofan Ke
Journal:  Exp Ther Med       Date:  2017-08-25       Impact factor: 2.447

7.  Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.

Authors:  Hiroharu Maegawa; Hitoshi Niwa
Journal:  Methods Mol Biol       Date:  2021

8.  Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Aderbal S Aguiar; Fabrine S M Tristão; Majid Amar; Caroline Chevarin; Laurence Lanfumey; Raymond Mongeau; Olga Corti; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-04-16       Impact factor: 3.911

9.  Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism.

Authors:  Naoki Inoue; Sae Ogura; Atsushi Kasai; Takanobu Nakazawa; Kazuya Ikeda; Shintaro Higashi; Ayako Isotani; Kousuke Baba; Hideki Mochizuki; Harutoshi Fujimura; Yukio Ago; Atsuko Hayata-Takano; Kaoru Seiriki; Yusuke Shintani; Norihito Shintani; Hitoshi Hashimoto
Journal:  EMBO Rep       Date:  2018-01-25       Impact factor: 8.807

10.  Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein.

Authors:  Matthew Benskey; Ki Yong Lee; Kevin Parikh; Keith J Lookingland; John L Goudreau
Journal:  Neurotoxicology       Date:  2013-05-01       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.